Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms
| Autor: | Thomas W. Flaig, Christopher Geiger, Nellowe Candelario |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Kidney Cancer. 5:167-179 |
| ISSN: | 2468-4570 2468-4562 |
| DOI: | 10.3233/kca-210126 |
| Popis: | Sarcomatoid renal cell carcinoma (sRCC) is an aggressive form of kidney cancer that is associated with poor prognosis. It can arise from any histologic type of renal cell carcinoma. The majority of cases will present with advanced or metastatic disease requiring systemic therapy. Nephrectomy is the treatment of choice in locally resectable disease. The therapeutic options for sRCC have evolved in the past decade. Cytotoxic chemotherapy and monotherapy with targeted therapy (VEGF and mTOR) have historically shown poor response rates and survival in the treatment of metastatic sRCC. The use of checkpoint inhibitors and their combination with targeted therapy against VEGF has changed the landscape and outcomes for renal cell carcinoma. Given the rarity of sRCC most of the data on treatment is from small cohorts or extrapolation from larger clinical trials. The benefit from the combination of checkpoint inhibitors and targeted therapy to VEGF has shown promise in the sRCC population in post hoc analysis of large clinical trials. Future research focusing on further characterizing the unique biologic and clinical features of sRCC is critical in advancing the knowledge and developing effective therapy to improve clinical outcomes and survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|